News
U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...
U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...
The Food and Drug Administration plans to ask Sarepta Therapeutics Inc. to pause shipments of its Elevidys treatment after ...
The move follows the death of two teenagers who were administered the treatment, as well as the death of a 51-year-old ...
The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene ...
The company had previously halted shipments to certain older patients following the deaths of two teenagers treated with the ...
Explore more
Three patients with a muscle-wasting disease died from liver failure after taking the therapy, Elevidys, or a similar ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
12h
GlobalData on MSNSarepta share price drops again after third gene therapy deathSarepta Therapeutics was approached for comment by Clinical Trials Arena but did not respond before publication. This comes ...
Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...
Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...
Sarepta Therapeutics announces layoffs of 493 employees, including 80 in Franklin County, amid restructuring efforts and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results